Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease
NCT02231346 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2014-09-04
Summary
New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® compared to a powder inhaler in patients with chronic obstructive lung disease (COLD). Moreover, further knowledge should be attained about the tolerability of Berodual® Respimat®
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG
-
Berodual® Respimat® - inhaler
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-10-31
- Primary Completion
- 2006-04-30
More Related Trials
-
Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02176200 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
NCT00267917 ·Status: COMPLETED ·Phase: PHASE4
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease
NCT02231424 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02232594 ·Status: COMPLETED
-
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00153075 ·Status: COMPLETED ·Phase: PHASE4
-
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
NCT01019694 ·Status: COMPLETED ·Phase: PHASE3
-
Re-usable Respimat® Soft MistTM Inhaler Study
NCT04011735 ·Status: COMPLETED
-
A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
NCT06297668 ·Status: COMPLETED ·Phase: PHASE1
-
12 / 48 Week Pivotal PFT vs PBO in COPD I
NCT00782210 ·Status: COMPLETED ·Phase: PHASE3
-
Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02244216 ·Status: COMPLETED
-
BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD
NCT00846768 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02236182 ·Status: COMPLETED ·Phase: PHASE2
-
A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
NCT03964207 ·Status: COMPLETED ·Phase: PHASE4
-
Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease
NCT01809262 ·Status: COMPLETED ·Phase: PHASE2
-
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
NCT00239473 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT05573464 ·Status: COMPLETED ·Phase: PHASE3
-
Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
NCT01760304 ·Status: TERMINATED ·Phase: PHASE4
-
Dose Finding Study in COPD
NCT00122434 ·Status: COMPLETED ·Phase: PHASE2
-
12 / 48 wk Pivotal PFT vs PBO in COPD II
NCT00782509 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
NCT00793624 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
NCT01040728 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment
NCT02384577 ·Status: COMPLETED
-
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
NCT00932646 ·Status: COMPLETED ·Phase: PHASE3
-
To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product
NCT02308098 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02236169 ·Status: COMPLETED ·Phase: PHASE2